Role of chemotherapy in patients with soft tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 4, Issue 2, 2004, Pages 229-236

  Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Doxorubucin; GIST; Ifosfamide; Imatinib; Sarcoma

Indexed keywords

ALKALINE PHOSPHATASE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AVASTATIN; BEVACIZUMAB; BILIRUBIN; BROSTALLICIN; CT 2584; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GONADORELIN AGONIST; IFOSFAMIDE; IMATINIB; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL KINASE; PROTEIN P53; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRABECTEDIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DRUG HALF LIFE; DRUG TARGETING; ENVIRONMENTAL FACTOR; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEREDITY; HUMAN; LUNG METASTASIS; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA;

EID: 1842639034     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.2.229     Document Type: Review

References (36)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
2. Brady M, Gaynor J, Brennan M. Radiation-associated sarcoma of bone and soft tissue. Arch. Surg. 127, 1379-1385 (1992).
3. Kelly S, Guidotti T. Phenoxyacetic acid herbicides and chlorophenols and the etiology of lymphoma and soft-tissue neoplasms. Public Health Rev. 17, 1-37 (1989-1990).
4. Li F, Fraumeni J Jr. Soft tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747-752 (1969).
5. Sorensen S, Mulvihill J, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. N. Engl. J. Med. 314, 1010-1015 (1986).
6. Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: An overview and update. Lancet Oncol. 1, 75-85 (2000).
7. Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 16, 197-203 (1998).
8. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J. Clin. Oncol. 14, 859-868 (1996).
9. Crist WM, Anderson JR, Meza JL et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
10. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694-701 (2003).
11. Goorin AM. Adjuvant chemotherapy for osteogenic sarcoma. Eur. J. Cancer Clin. Oncol. 24, 113-115 (1988).
12. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350, 1647-1654 (1997).
13. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult STS of the extremities and girdles: Results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238-1247 (2001).
14. Frustaci S, De Paoli A, Bidoli E et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65, 80-84 (2003).
15. Brodowicz T, Schwameis E, Widder J et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: A prospective randomized feasibility trial. Sarcoma 4, 151-160 (2000).
16. Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neoadjuvant chemotherapy for high-risk adult soft-tissue sarcoma. Eur. J. Cancer 37, 1096-1103 (2001).
17. Phan A, Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr. Treat. Options Oncol. 4, 433-439 (2003).
18. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85, 389-395 (1999).
19. Brennan MF, Alektiar K, Maki RG. Soft tissue sarcoma In: Cancer: Principles & Practice of Oncology (6th edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, PA, USA, 1841-1891 (2001).
20. Lorigan PC, Verweij J, Papai Z et al. Randomised Phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma (ASTS). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 1616).
21. Judson I, Radford JA, Harris M et al. Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37, 870-877 (2001).
22. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269-1275 (1993).
23. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
24. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
25. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer 39, 2006-2011 (2003).
26. Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 89, 391-396 (2003).
27. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 97, 1134-1135 (2003).
28. Eggermont AM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg. Oncol. Clin. N. Am. 12, 469-483 (2003).
29. Demetri GD. ET-743: The US experience in sarcomas of soft tissues. Anticancer Drugs 13(Suppl. 1), S7-S9 (2002).
30. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin. Investig. Drugs 12, 1843-1853 (2003).
31. Jimeno J, Maki RG, Casali P et al. Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma. Curr. Opin. Orthop. 14, 419-428 (2003).
32. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543-549 (2002).
33. Lopez-Martin JA, Verweij J, Blay J et al. An exploratory analysis of tumor growth rate (TGR) variations induced by trabectedin (ecteinascidin-743, ET-743) in patients (pts) with pretreated advanced soft tissue sarcoma (PASTS). Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 3293).
34. Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9, 1648-1655 (2003).
35. Keohan ML, Taub R, Plitsas M et al. Phase II study of CT-2584, a novel inhibitor of phosphatidylcholine biosynthesis, in patients with soft tissue sarcoma. Proc. Am. Soc. Clin. Oncol. 19 (2000) (Abstract 2187).
36. Schmitt CA, Fridman JS, Wang M et al. Dissecting p53 tumor suppressor function in vivo. Cancer Cell 1, 289-298 (2002).